Piramal Pharma Reports Q2 Profit, Raises FY27 Guidance, Cuts China Raw Material Dependence
Piramal Pharma reported a consolidated net profit of Rs 5 crore in Q2 FY27, reversing previous losses and surpassing market expectations with over 28% revenue growth. The company raised its FY27 revenue growth guidance to 19-20%, expecting profitability by year-end. It has reduced reliance on Chinese raw materials to under 10% to manage supply-chain risks, diversifying manufacturing across India, the UK, and the US. Shares surged to an 18-month high following the positive results and outlook.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (67/100). Lens Score 35/100.
Outlets measured: thefinancialexpress, moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 28 Oct, 12:46 pm. Other outlets followed.